MA32719B1 - Formulations galeniques de composes organiques - Google Patents

Formulations galeniques de composes organiques

Info

Publication number
MA32719B1
MA32719B1 MA33780A MA33780A MA32719B1 MA 32719 B1 MA32719 B1 MA 32719B1 MA 33780 A MA33780 A MA 33780A MA 33780 A MA33780 A MA 33780A MA 32719 B1 MA32719 B1 MA 32719B1
Authority
MA
Morocco
Prior art keywords
organic compounds
galenic formulations
galenic
formulations
aliskirin
Prior art date
Application number
MA33780A
Other languages
Arabic (ar)
English (en)
Inventor
Stephen Valazza
Robert Frank Wagner
Sudha Vippagunta
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42040192&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32719(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA32719B1 publication Critical patent/MA32719B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une combinaison pharmaceutique orale à dose fixe renfermant a) une quantité thérapeutiquement efficace d'aliskirène ou d'un sel pharmaceutiquement acceptable correspondant, b) une quantité thérapeutiquement efficace d'amlodipine ou d'un sel pharmaceutiquement acceptable correspondant, la combinaison pharmaceutique orale à dose fixe présentant une dissolution
MA33780A 2008-09-22 2011-04-15 Formulations galeniques de composes organiques MA32719B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9894508P 2008-09-22 2008-09-22
PCT/US2009/057750 WO2010033954A2 (fr) 2008-09-22 2009-09-22 Formulations galéniques de composés organiques

Publications (1)

Publication Number Publication Date
MA32719B1 true MA32719B1 (fr) 2011-10-02

Family

ID=42040192

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33780A MA32719B1 (fr) 2008-09-22 2011-04-15 Formulations galeniques de composes organiques

Country Status (21)

Country Link
US (1) US8613949B2 (fr)
EP (1) EP2328564A2 (fr)
JP (2) JP2012503020A (fr)
KR (1) KR20110060942A (fr)
CN (1) CN102159195A (fr)
AR (1) AR073384A1 (fr)
AU (1) AU2009292908B2 (fr)
BR (1) BRPI0919350A2 (fr)
CA (1) CA2736257A1 (fr)
CL (1) CL2011000594A1 (fr)
CO (1) CO6351711A2 (fr)
EC (1) ECSP11010999A (fr)
IL (1) IL211571A0 (fr)
JO (1) JO3239B1 (fr)
MA (1) MA32719B1 (fr)
MX (1) MX2011002988A (fr)
MY (1) MY153610A (fr)
PE (1) PE20110293A1 (fr)
RU (2) RU2014140552A (fr)
TW (1) TW201016217A (fr)
WO (1) WO2010033954A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110268797A1 (en) * 2010-04-30 2011-11-03 Sanovel IIac Sanayi Ve Ticaret Anonim Sirketi Multicoated aliskiren formulations
CN102247344A (zh) * 2011-05-30 2011-11-23 北京阜康仁生物制药科技有限公司 一种新型降血压组合物
CN103070863A (zh) * 2011-10-25 2013-05-01 河南省健康伟业生物医药研究股份有限公司 阿利吉仑和氨氯地平/左旋氨氯地平的口服固体制剂的制备新工艺
US20180338922A1 (en) * 2017-05-26 2018-11-29 Esperion Therapeutics, Inc. Fixed dose formulations

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003032954A1 (fr) 2001-10-17 2003-04-24 Dr. Reddy's Laboratories Ltd. Formulations pharmaceutiques stabilisees contenant du maleate d'amlodipine
HU226642B1 (en) 2001-12-17 2009-05-28 Egis Gyogyszergyar Nyilvanosan Amlodipine bezylate tablets having extended stability and process for producing the same
CA2485081C (fr) 2002-05-17 2013-01-08 Novartis Ag Composition pharmaceutique comprenant un inhibiteur de renine, un agent de blocage du canal du calcium et un diuretique
DE10223282B3 (de) 2002-05-24 2004-02-05 Orga Kartensysteme Gmbh Verfahren, Computerprogramm und Computersystem für einen prepaid Telekommunikationsdienst
FR2853904B1 (fr) 2003-04-15 2007-11-16 Air Liquide Procede de production de liquides hydrocarbones mettant en oeuvre un procede fischer-tropsch
MY144477A (en) * 2004-03-17 2011-09-30 Novartis Ag Galenic formulations of organic compounds
TW200605867A (en) * 2004-03-17 2006-02-16 Novartis Ag Use of organic compounds
RS53141B (en) 2004-11-05 2014-06-30 Boehringer Ingelheim International Gmbh TWO-LAYER TABLE CONTAINING TELMISARTAN AND AMLODIPINE
US20060116435A1 (en) * 2004-12-01 2006-06-01 Housel Tyler L High strength polyurethane foam
WO2006059217A1 (fr) * 2004-12-01 2006-06-08 Ranbaxy Laboratories Limited Formes posologiques solides stables d'amlodipine bezylate, et procedes d'elaboration correspondants
GT200600371A (es) 2005-08-17 2007-03-21 Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
PE20120542A1 (es) 2006-06-27 2012-05-14 Novartis Ag Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas
US20080161320A1 (en) 2006-09-11 2008-07-03 Xiong Cai Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety
PE20081157A1 (es) * 2006-11-07 2008-09-26 Novartis Ag Forma cristalina de hemifumarato de alisquireno

Also Published As

Publication number Publication date
WO2010033954A2 (fr) 2010-03-25
RU2014140552A (ru) 2015-06-20
JP2015091830A (ja) 2015-05-14
CL2011000594A1 (es) 2011-08-05
TW201016217A (en) 2010-05-01
RU2011115712A (ru) 2012-10-27
CA2736257A1 (fr) 2010-03-25
JP2012503020A (ja) 2012-02-02
US20110165240A1 (en) 2011-07-07
KR20110060942A (ko) 2011-06-08
JO3239B1 (ar) 2018-03-08
AR073384A1 (es) 2010-11-03
WO2010033954A3 (fr) 2010-10-21
PE20110293A1 (es) 2011-05-17
MY153610A (en) 2015-02-27
US8613949B2 (en) 2013-12-24
AU2009292908A1 (en) 2010-03-25
CN102159195A (zh) 2011-08-17
AU2009292908B2 (en) 2012-07-26
BRPI0919350A2 (pt) 2015-12-29
CO6351711A2 (es) 2011-12-20
EP2328564A2 (fr) 2011-06-08
IL211571A0 (en) 2011-05-31
ECSP11010999A (es) 2011-06-30
MX2011002988A (es) 2011-04-11

Similar Documents

Publication Publication Date Title
NZ605887A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain
EA200901277A1 (ru) Фармацевтические составы, содержащие пропиленгликольгидрат дапаглифлозина
TN2012000421A1 (en) Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
MX356032B (es) Compuestos indola y métodos para tratar el dolor visceral.
CO6361928A2 (es) Modulares de aril metil benzoquinazolinona alostericos positivos del receptor m1
BRPI0707235B8 (pt) formulação de fentanil sublingual sem propelente, e, dispositivo de dose unitária para administração sublingual de uma formulação de fentanil sublingual
MX2011012627A (es) Derivados aminobutiricos sustituidos como inhibidores de nepralisina.
ATE517882T1 (de) Chinolinderivate
MX354423B (es) Formulaciones de rasagilina de liberación prolongada y usos de las mismas.
UA110012C2 (uk) Лікарські форми для перорального застосування, що містять ацетат лікарбазепіну
WO2008027350A3 (fr) Compositions pharmaceutiques à base d'acétaminophène
NO20043367L (no) Oralt farmasoytisk preparat
EA200870448A1 (ru) Тризамещенные 1,2,4-триазолы
WO2011047173A3 (fr) Compositions pharmaceutiques à usage oral
DE602008005582D1 (de) Pyrazolderivate als p2x7-modulatoren
TR201900199T4 (tr) Oksikodon ve nalokson içeren çabuk salımlı farmasötik bileşimler.
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
GEP20135744B (en) Quinuclidine carbonate derivatives and medicinal compositions containing the same
ZA200801575B (en) Pharmaceutical formulations/composition of guanfacine suitable for single dose form administration daily
GEP20135806B (en) Lactams as beta secretase inhibitors
CY1113759T1 (el) Ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
BR112012023178A2 (pt) ramidinas substituídas como antagonistas de receptor prostaglandina 2
IN2012DN02502A (fr)
MA32719B1 (fr) Formulations galeniques de composes organiques
WO2006079077A3 (fr) Composes en tant que modulateurs de recepteur de ghreline et leurs utilisations